prism statistical package graphpad instat version 6.1 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
prism statistical package graphpad instat version 6.1
Prism Statistical Package Graphpad Instat Version 6.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism+statistical+package+graphpad+instat+version+6%2E1/prism+statistical+package+graphpad+instat+version+6+1/pm25381986-25-9-12
Average 90 stars, based on 1 article reviews
Prism Statistical Package Graphpad Instat Version 6.1, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prism+statistical+package+graphpad+instat+version+6%2E1/prism+statistical+package+graphpad+instat+version+6+1/pm25381986-25-9-12
Average 90 stars, based on 1 article reviews
prism statistical package graphpad instat version 6.1 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response. Article Snippet: Patients with active rheumatoid arthritis (RA) frequently show an atherogenic lipid profile, which has been linked with the inflammatory reaction.. Inflammatory cytokines, and particularly tumor necrosis factor-alpha (TNF-α), are implicated in the pathogenesis of both atherosclerosis and RA, and also involved in the development of the impaired lipid profile detected in active RA.. Although anti-TNF-α agents have been proven effective in controlling joint damage and systemic inflammation, controversy remains about the effect of these drugs on the lipid profile; therefore, the aim of our study was to investigate the effect of anti-TNF-α treatment, in combination with disease-modifying antirheumatic drugs (DMARDs) and corticosteroid therapy, on the lipid profile of patients with active RA. |